NEI Research News

A 28-patient phase 1 gene therapy clinical trial for the degenerative retinal disease Leber hereditary optic neuropathy (LHON) found no significant safety concerns; however, treatment failed to improve or slow vision loss, with even the highest dose.

Researchers have identified distinct differences among the cells comprising a tissue in the retina that is vital to human visual perception. The scientists from the National Eye Institute (NEI) discovered five subpopulations of retinal pigment epithelium.

Molecular and cellular changes in rod photoreceptors are detectable in a mouse model of retinal degeneration several days prior to observable morphological changes, according to researchers at the National Eye Institute.

NIH-funded study finds many patients with retinal vein occlusion have vision benefits, but require long-term monitoring and treatment

The road from discovering a potential drug to getting the therapy into the hands of patients is a long and uncertain one. An NIH program called Blueprint Neurotherapeutics Network helps basic researchers prep for clinical trials and regulatory approval.

New research by National Eye Institute (NEI) investigators shows that while microsaccades seem to boost or diminish the strength of the brain signals underlying attention, eye movements are not drivers of those brain signals.

The digital summit of global partners in vision research discussed opportunities for collaboration.

Researchers at the National Eye Institute (NEI) have discovered that power-producing organelles in the eye’s photoreceptor cells, called mitochondria, function as microlenses that help channel light to these cells’ outer segments.

Part of the Anterior Segment Initiative, the meeting addressed gaps in knowledge, barriers to new therapies, and promising areas for research.

National Eye Institute researchers developed and validated an artificial-intelligence-based method to evaluate patients with Stargardt, an eye disease that can lead to childhood vision loss.